Black Diamond Therapeutics BDTX Stock
Black Diamond Therapeutics Price Chart
Black Diamond Therapeutics BDTX Financial and Trading Overview
| Black Diamond Therapeutics stock price | 1.8 USD |
| Previous Close | 1.89 USD |
| Open | 1.9 USD |
| Bid | 1.39 USD x 200 |
| Ask | 2.43 USD x 200 |
| Day's Range | 1.88 - 1.95 USD |
| 52 Week Range | 1.6 - 4.94 USD |
| Volume | 838.34K USD |
| Avg. Volume | 663.94K USD |
| Market Cap | 111.46M USD |
| Beta (5Y Monthly) | 3.325 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.75 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10 USD |
BDTX Valuation Measures
| Enterprise Value | 17.92M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.94 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 1.1595936 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.404 |
Trading Information
Black Diamond Therapeutics Stock Price History
| Beta (5Y Monthly) | 3.325 |
| 52-Week Change | -50.38% |
| S&P500 52-Week Change | 15.77% |
| 52 Week High | 4.94 USD |
| 52 Week Low | 1.6 USD |
| 50-Day Moving Average | 1.98 USD |
| 200-Day Moving Average | 2.27 USD |
BDTX Share Statistics
| Avg. Volume (3 month) | 663.94K USD |
| Avg. Daily Volume (10-Days) | 554.56K USD |
| Shares Outstanding | 57.45M |
| Float | 52.51M |
| Short Ratio | 9.53 |
| % Held by Insiders | 0.66% |
| % Held by Institutions | 72.58% |
| Shares Short | 5.15M |
| Short % of Float | 12.87% |
| Short % of Shares Outstanding | 8.95% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.11% |
| Return on Equity (ttm) | -37.21% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 0 USD |
| EBITDA | -44349000 USD |
| Net Income Avi to Common (ttm) | -42555000 USD |
| Diluted EPS (ttm) | -0.75 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 110.51M USD |
| Total Cash Per Share (mrq) | 1.92 USD |
| Total Debt (mrq) | 16.97M USD |
| Total Debt/Equity (mrq) | 17.66 USD |
| Current Ratio (mrq) | 7.284 |
| Book Value Per Share (mrq) | 1.673 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -32837000 USD |
| Levered Free Cash Flow (ttm) | -23577500 USD |
Profile of Black Diamond Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 245 First Street |
| ZIP | 02142 |
| Phone | 617 252 0848 |
| Website | https://www.blackdiamondtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 21 |
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Q&A For Black Diamond Therapeutics Stock
What is a current BDTX stock price?
Black Diamond Therapeutics BDTX stock price today per share is 1.8 USD.
How to purchase Black Diamond Therapeutics stock?
You can buy BDTX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Black Diamond Therapeutics?
The stock symbol or ticker of Black Diamond Therapeutics is BDTX.
Which industry does the Black Diamond Therapeutics company belong to?
The Black Diamond Therapeutics industry is Biotechnology.
How many shares does Black Diamond Therapeutics have in circulation?
The max supply of Black Diamond Therapeutics shares is 57.45M.
What is Black Diamond Therapeutics Price to Earnings Ratio (PE Ratio)?
Black Diamond Therapeutics PE Ratio is now.
What was Black Diamond Therapeutics earnings per share over the trailing 12 months (TTM)?
Black Diamond Therapeutics EPS is -0.75 USD over the trailing 12 months.
Which sector does the Black Diamond Therapeutics company belong to?
The Black Diamond Therapeutics sector is Healthcare.
Black Diamond Therapeutics BDTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27150.43 USD — |
-1.41
|
5.55B USD — | 27066.76 USD — | 27491.9 USD — | — - | 5.55B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13367.48 USD — |
-1.43
|
— — | 13329.2 USD — | 13540.94 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6806.1 USD — |
-1.06
|
— — | 6678.62 USD — | 6820.47 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1285.38 USD — |
-0.8
|
— — | 1265.56 USD — | 1285.6 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
